An initiative to improve pediatric TB treatment with the goal of ensuring all children with TB receive appropriate treatment.

NEW YORK, NY – TB Alliance, an international non-profit drug development organization that develops better, faster-acting, and affordable tuberculosis (TB) drugs, announced today that it has assigned certain patents covering novel bi-functional compounds and related assets to TenNor Therapeutics, a biotech company based in Suzhou, China. These compounds were originally discovered by TB Alliance as part of its TB drug discovery effort. Although they were found not to be suitable in treating TB, they may hold value in treating infectious diseases of the gastrointestinal (GI) tract.

30 October 2013 (PARIS, FRANCE): In an effort to develop and deliver treatments for children with tuberculosis (TB)—answering a critical need in public health today—TB Alliance, a not-for-profit organization with the mission to develop better, faster-acting, and affordable drugs for TB, has entered into a collaboration with Svizera Europe, one of the leading global supply and distribution companies for TB treatments. The partnership aims to create and enable access to new medicines for childhood TB. Tuberculosis is among the top 10 killers of children and an estimated 500,000 children have TB, but many suspect the burden could be much higher.

New York, USA: The Global Alliance for TB Drug Development (TB Alliance) has received a grant from the Australian Agency for International Development (AusAID) to support the advancement of the largest pipeline of potential new TB drugs. This one-year $2.5 million grant funds further development of urgently needed new TB treatments to combat the global epidemic, which is growing increasingly resistant to today’s available therapies. TB Alliance received this support as part of Australia’s first set of grants to fund new product development to treat diseases of poverty.

TB Alliance and its partners manage the largest pipeline of potential new TB drugs and drug regimens in history. A newly launched web-based tool allows users to follow the progress of TB Alliance research and development programs, offering key information on each project, clinical trial, and experimental regimen undergoing development.

The Global Health Innovative Technology Fund (GHIT Fund), a new public-private partnership that’s bringing Japanese research and development (R&D) to the global fight against infectious disease, will announce at the 5th Tokyo International Conference on African Development (TICAD V) a series of historic agreements to screen compound libraries at Japanese pharmaceutical companies and research institutes for new treatments for malaria, tuberculosis, and other afflictions that prey mainly on the poorest of the poor.

TB Alliance, an international non-profit organization which develops better, faster-acting, and affordable TB drugs, has announced that it has granted a license to and is working with the Open Source Drug Discovery (OSDD) programme of Council of Scientific and Industrial Research (CSIR) to develop and commercialize a promising new tuberculosis (TB) regimen for use within India. CSIR is an Indian governmental institution, which provides scientific and industrial R&D that maximizes the economic, environmental, and societal benefits for the people of India.

In TB fight, children must be a priority – World TB Day March 24

Pyrazinamide (PZA) is an incredibly important sterilizing agent in the treatment of tuberculosis and is considered responsible for reducing the duration of treatment from the previous 9-12 months, to the current short-course of 6 months produced by the standard regimen (HRZE).Beyond its contribution in the current  first-line regimen, the TB Alliance, through its ongoing novel regimen development program is finding that PZA is critical to any treatment shortening regimen, including those that contain newer agents currently in clinical development.  PZA has the ability to synergize with other drugs and this synergy drives the treatment-shortening potential of experimental regimens, such as PaMZ (PA-824 + moxifloxacin + pyrazinamide) currently under clinical development. However, resistance to PZA is on the rise, creating potential problems for PZA-containing regimens in development. Yet, there may be ways to circumvent this resistance. Investigating whether this is possible is the focus of a 1-year, $250,000 grant from the US NIH ACTG.

Grant to reshape market forces, catalyze development to improve treatment of childhood TB.